Investors

Change

Volume

52 Week High

52 Week Low

Apr 12, 2019 3:22 AM EDT

Email Alerts

Sign up to receive e-mail alerts whenever IMV Inc. posts new information to the site. Click here to choose your subscriptions.

HC Wainwright Global Life Sciences Conference

Apr 9, 2019 at 1:10 PM BST

Listen to Webcast

Supporting Materials

View Presentation 1.6 MB

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

Research & Development

Intellectual Property